The 2004 Bachem catalog covers peptides, proteins, and related immunochemicals, enzyme inhibitors and substrates, amino acid derivatives, resins, and organic compounds.
This company has released a catalog of bioanalytical sample preparation products for scientists isolating drug candidates from biological fluids in discovery support, pre-clinical, and clinical studies.
The Active Motif 2004 catalog features a variety of products for transcription factor, cell
by Elizabeth Tolchin A series of new human protein microarray, set to hit the market later this year, are already making a good impression on researchers at Yale who are looking for kinases involved in chronic myelogenous leukemia (CML).
by Elizabeth Tolchin Researchers looking for genes involved in complex neurological and psychiatric illnesses are using a new software tool for handling high-throughput genotyping assays.
by Elizabeth Tolchin A novel combination of a tumor suppressor with a growth factor inhibitor is yielding promising results for breast cancer.
by Elizabeth Tolchin In a pharmacogenomic study, researchers found a genetic marker related to immune response for Stevens-Johnson syndrome (SJS), a life-threatening skin condition brought about by an adverse reaction to certain medications.
by Elizabeth Tolchin By using past experience from the study of fusion-inhibitory peptides in HIV, researchers found a similar inhibitory mechanism for severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV).
by Elizabeth Tolchin A contract research organization was granted a patent this week that covers the use of zebrafish ( Danio rerio ) for drug screening using microliter plates.
by Elizabeth Tolchin By developing a novel antibody drug discovery technology, researchers from Texas Tech University, Amarillo, Texas, spawned a start-up firm, now six weeks young. Venture capital firm Emergent Technologies Inc., Austin, Texas, licensed the technology from the university and formed the start-up, Receptor Logic Ltd.
by Elizabeth Tolchin The FDA approved a new cancer treatment candidate by Genentech Inc., South San Francisco, called Avastin, this February. A recombinant humanized antibody to vascular endothelial growth factor (VEGF), the drug is designed to bind to and inhibit VEGF, a protein that plays a role in tumor angiogenesis.
by Elizabeth Tolchin In support of the US Food and Drug Administration (FDA) initiative on the use of pharmacogenomic data in the drug submission process, Iconix Pharmaceuticals Inc. is releasing a set of its proprietary Drug Signature genomic biomarkers to the scientific community for research and validation.
by Elizabeth Tolchin A structure-guided drug discovery company is using software that allows their bench chemists to handle library design and enumeration. Optive Research Inc., recently deployed the software, called Benchware, for Structural GenomiX (SGX).
by Elizabeth Tolchin Researchers involved in comparative studies of bacterial genomes devised an application of microarray technology in which whole genomes are arrayed on a single glass slide and probed for the presence or absence of specific genes or alleles.
by Elizabeth Tolchin Researchers at the European Molecular Biology Laboratory (EMBL) and the German Cancer Research Centre (DKFZ), both based in Heidelberg, Germany, have a new Chemical Genomics Facility to call their own. It is one of the first academic facilities for small-molecule screening in Europe.